NCT03539016

Brief Summary

The study was conducted to observe the clinical features during pregnancy in women with chronic hepatitis B virus infection and mother-to-child transmission of hepatitis B virus.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2015

Typical duration for all trials

Geographic Reach
1 country

10 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2018

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

May 16, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

May 29, 2018

Completed
Last Updated

May 29, 2018

Status Verified

April 1, 2018

Enrollment Period

2.6 years

First QC Date

May 16, 2018

Last Update Submit

May 25, 2018

Conditions

Keywords

Chronic hepatitis B, Mother-to-child transmission

Outcome Measures

Primary Outcomes (2)

  • Rate of mother-to-child transmission

    Infants from 7 to 12 months of age

  • Rate of hepatitis flare during pregnancy and postpartum

    up to postpartum weeks 6-8

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Pregnant woman

You may qualify if:

  • Gestation of 4-32 weeks
  • HBsAg+ \> 6 months, HBeAg+/-
  • Informed consent signed voluntarily
  • Good compliance and able to be followed up as planned

You may not qualify if:

  • Coinfection with hepatitis C virus or human immunodeficiency virus;
  • Comorbidities of other severe conditions that hinder compliance with follow ups and because of that, the subjects are anticipated to be unable to complete the project.;
  • Unable or unwilling to use mobile health tools.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Nanfang Hospital

Guangzhou, Guangdong, China

Location

302 military hospital of China

Beijing, China

Location

Beijing YouAn Hospital

Beijing, China

Location

Fifth Affiliated Hospital of Southern Medical University

Guangzhou, China

Location

Guangzhou No. 8 People's Hospital

Guangzhou, China

Location

Third Affiliated Hospital of Southern Medical University

Guangzhou, China

Location

Zhujiang Hospital

Guangzhou, China

Location

Jiujiang Maternal and Child Care Service Centre

Jiujiang, China

Location

Third Hospital of Jiujiang

Jiujiang, China

Location

Second Hospital of Nanjing

Nanjing, China

Location

MeSH Terms

Conditions

Hepatitis B, Chronic

Condition Hierarchy (Ancestors)

Hepatitis BBlood-Borne InfectionsCommunicable DiseasesInfectionsHepadnaviridae InfectionsDNA Virus InfectionsVirus DiseasesHepatitis, Viral, HumanHepatitis, ChronicHepatitisLiver DiseasesDigestive System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 16, 2018

First Posted

May 29, 2018

Study Start

July 1, 2015

Primary Completion

February 1, 2018

Study Completion

May 1, 2018

Last Updated

May 29, 2018

Record last verified: 2018-04

Locations